Objective: To assess outcomes after treatment for asymptomatic abdominal aortic aneurysm (AAA) in Denmark in a period when both open surgery (OR) and endoluminal repair (EVAR) have been routine procedures.
Methods: We performed a retrospective nationwide cohort study of patients treated for asymptomatic AAA between 2007 and 2010. Data on demographics, procedural data, perioperative complications, length of stay (LOS), 30-day reinterventions and readmissions, late aneurysm and procedure-related complications and mortality were obtained from the Danish Vascular Registry and the Danish National Patient Register.
Results: 525 EVAR and 1176 OR for asymptomatic AAA were identified. LOS was shorter after EVAR than OR (4 vs 7 days, P < .001). During primary hospitalization procedure-related complications (12% vs 6%) and general complications (21% vs 8%) were more common after OR than EVAR (P < 0.001). The 30-day reintervention rate was higher for OR than EVAR (18% vs 6%, P < 0.001), but there was no difference in readmissions within 30 days. During follow-up (mean 29 6 15 months) aneurysm-related complications after EVAR were outweighed by procedure-related complications after OR.
Conclusion: Elective AAA repair in Denmark is overall comparable with international results and both perioperative and late outcomes after EVAR of elective AAA are better than the results after OR. Objective: Treatment of abdominal aortic aneurysms with high-risk anatomy (neck length <10-15 mm, neck angle >60 ) using commercially available devices has become increasingly common with expanding institutional experience. We examined whether placement of approved devices in short angled necks provides acceptable durability at early and intermediate time points.
EVAR Deployment in Anatomically Challenging
Methods: A total of 218 patients (197 men, 21 women) at a single academic center underwent endovascular aneurysm repair (EVAR) with a commercially available device between January 2004 and December 2007. Available medical records, pre-and postoperative imaging, and clinical follow-up were retrospectively reviewed. Patients were divided into those with suitable anatomy (instructions for use, IFU) for EVAR and those with high-risk anatomic aneurysm characteristics (non-IFU).
Results: IFU (n = 143) patients underwent repair with Excluder (40%), AneuRx (34%), and Zenith (26%) devices, whereas non-IFU (n = 75) were preferentially treated with Zenith (57%) over Excluder (25%) and AneuRx (17%). Demographics and medical comorbidities between the groups were similar. Operative mortality was 1.4% (2.1% IFU, 0% non-IFU) with mean follow-up of 35 months (range 12-72). Non-IFU patients tended to have larger sac diameters (46.7% $60 mm) with shorter (30.7% #10 mm), conical (49.3%), and more angled (68% >60
) necks (all P < .05 compared with IFU patients). Operative characteristics revealed that the non-IFU patients were more likely to be treated utilizing suprarenal fixation devices, to require placement of proximal cuffs (13.3% vs 2.1%, P = .003), and needed increased fluoroscopy time (31 vs 25 minutes, P = .02). Contrast dose was similar between groups (IFU = 118 mL, non-IFU = 119 mL, P = .95). There were no early or late surgical conversions. Rates of migration, endoleak, need for reintervention, sac regression, and freedom from aneurysm-related death were similar between the groups (P > .05).
Conclusions: EVAR may be performed safely in high-risk patients with unfavorable neck anatomy using particular commercially available endografts. In our experience, the preferential use of active suprarenal fixation and aggressive use of proximal cuffs is associated with optimal results in these settings. Mid-term outcomes are comparable with those achieved in patients with suitable anatomy using a similar range of EVAR devices. Careful and mandatory long-term follow-up will be necessary to confirm the benefit of treating these high-risk anatomic patients.
Centerline is Not as Accurate as Outer Curvature Length to Estimate Thoracic Endograft Length
Kaladji A., Spear R., Hertault A., Sobocinski J., Maurel B., Haulon S. Eur J Vasc Endovasc Surg 2013;46:82-6.
Background: To assess the accuracy of the aortic outer curvature length for thoracic endograft planning.
Methods: Seventy-four patients (58 men, 66.4 6 14 years) who underwent thoracic endovascular aortic repair between 2009 and 2011 treated with a Cook Medical endograft were enrolled in this retrospective study. Immediate postoperative CT scans were analysed using EndoSize software. Three vessel lengths were computed between two fixed landmarks placed at each end of the endograft: the straightline (axial) length, the centerline length and the outer curvature length. A tortuosity index was defined as the ratio of the centerline length/straightline length. A Student t test and a Pearson correlation coefficient were used to examine the results.
Results: We found a significant difference between the centerline length (135.4 6 24 mm) and that of the endograft (160 6 29 mm) (P < .0001). This difference correlates with the tortuosity index (r = .818, P < .0001), the endograft length (r = .587, P < .0001), and the diameter of the endograft (r = .53, P < .0001). However, the outer curvature length (161.3 6 29 mm) and the endograft length (160 6 29 mm) were similar (P = .792).
Conclusion: The outer curvature length more accurately reflects that of the deployed endograft and may prove more accurate than centerlines in planning thoracic endografts. Objective: This study aimed to evaluate the outcome and predisposing factors related to perioperative bleeding in patients treated with endovascular aneurysm repair (EVAR) for ruptured and non-ruptured abdominal aortic aneurysm (AAA).
Perioperative Haemorrhage in Endovascular Abdominal
Design: This was a retrospective cohort study. Methods: A total of 525 consecutive patients (73% elective) with AAA underwent EVAR at two vascular centres from 2008 to 2011. From registry data perioperative bleeding was analysed in relation to outcome and preoperative data.
Results: A total of 453 (86%) patients presented with a perioperative bleeding <1000 mL, 42 (8%) patients 1000-1999 mL, 19 (4%) patients 2000-5000 mL and 11 (2%) >5000 mL. Other than ruptured AAA (n = 90), no preoperative risk factors for increased perioperative bleeding were found. Open femoral artery access (n = 101), branched (n = 18) and uni-iliacal endografts (n = 18) and introducer size were associated with increased perioperative bleeding (P < .001). In multivariable logistic regression only rupture and perioperative bleeding >2000 mL were significantly related to 30-day mortality (odds ratio 10.6 (range 3.8-29.6) and 13.4 (range 4.8-37.4), respectively). Postoperative renal failure, multi-organ failure, >5 days at intensive care unit, bowel ischaemia and abdominal compartments syndrome were significantly related to perioperative bleeding >2000 mL (P < .001).
Conclusion: Large perioperative bleeding during EVAR is a clinical problem that affects outcome. About 10% of elective AAA patients and 34% of patients with ruptured AAA, undergoing EVAR, present a perioperative blood loss exceeding 1 L. In our study, a perioperative blood loss exceeding 2 L was independently associated with increased mortality and morbidity in both acute and elective AAA patients. Open femoral access, branched EVAR and larger diameter introducers were associated with increased perioperative blood loss.
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